Actionable news
All posts from Actionable news
Actionable news in MSTX: MAST THERAPEUTICS Inc,

Mast Therapeutics Announces Appointment Of Matthew Pauls To Board Of Directors

SAN DIEGO, Nov. 2, 2015 /PRNewswire/ -- Mast Therapeutics, Inc. (nyse mkt:MSTX), a clinical-stage biopharmaceutical company leveraging its molecular adhesion and sealant technology (MAST) platform to develop novel therapies for sickle cell disease, heart failure, and stroke, today announced that Matthew Pauls has been appointed to the Company's Board of Directors, effective immediately.

Mr. Pauls brings more than 20 years of experience in the pharmaceutical industry, including senior leadership roles in a broad spectrum of operational areas and significant experience in new product launches, commercial and technical operations, as well as clinical development, with a specific focus on orphan drug candidates.

"We are delighted to have an executive of Matt's caliber join our Board, particularly as we near the completion of our Phase 3 'EPIC' study and begin to orient toward product commercialization," stated Brian M. Culley, Chief Executive Officer. "Matt's extensive experience and success in commercial strategy and operations, including with therapies for rare diseases, will be a significant asset for Mast."

Mr. Pauls currently serves as President and Chief Executive Officer and on the board of directors of Strongbridge Biopharma plc SBBP, -3.26% a biopharmaceutical company focused on therapies that target rare diseases. Prior to joining Strongbridge, Mr. Pauls was Chief Commercial Officer of Insmed, Inc., a global biopharmaceutical company focused on rare diseases. Prior to Insmed, Mr. Pauls served as senior vice president, head of global commercial operations at Shire Pharmaceuticals, a global specialty biopharmaceutical company. Earlier in his career, Mr. Pauls also held senior positions at Bristol-Myers Squibb in Brand Management and Payor Marketing, and at Johnson & Johnson in various U.S. and global commercial roles. Mr. Pauls holds B.S. and M.B.A. degrees from Central Michigan University and a J.D. from Michigan State University College of Law.

"I am pleased to join Mast Therapeutics' Board of Directors at such an exciting time in the Company's development. I look forward to contributing my experience and helping to further Mast's efforts to deliver new therapeutic options for serious and life-threatening diseases with significant unmet needs, such as sickle cell disease, heart failure and stroke," said Mr. Pauls.

About Mast Therapeutics Mast Therapeutics, Inc. is a publicly traded biopharmaceutical company...